Alexion’s Soliris Slips Up In Pivotal PROTECT Kidney Transplant Study
A difficult December for Alexion sees a pivotal study of its blockbuster Soliris failing to show any benefit in preventing delayed graft function in kidney transplant patients, an indication for which there are no approved treatments.
You may also be interested in...
Apellis Pharmaceuticals' lead product APL-2 for geographic atrophy, a progressed form of age-related macular degeneration, has met its primary endpoint in a Phase II trial with the company planning to begin Phase III trials in 2018.
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?
Keeping Track: Arymo ER Approved, Parsabiv Returns, Merck Surprises With Keytruda Chemo Combo Submission
The latest drug development news and highlights from our FDA Performance Tracker.